Aurinia Pharmaceuticals Inc. Stockholders Equity

Quick Answer

Aurinia Pharmaceuticals Inc. reported Stockholders Equity of $581.33 million for fiscal year 2025.

Aurinia Pharmaceuticals Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $581.33M +54.0%
2024 $377.48M -0.1%
2023 $377.95M -6.8%
2022 $405.44M -15.4%
2021 $479.09M +17.5%
2020 $407.75M +36.6%
2019 $298.60M +120.0%
2018 $135.72M -23.7%
2017 $177.92M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $365.77M -5.7% +9.1%
June 30, 2025 $335.30M -8.0% -4.3%
March 31, 2025 $350.19M -2.6% -7.2%
December 31, 2024 $377.48M -0.1% -2.7%
September 30, 2024 $388.00M -1.0% +6.4%
June 30, 2024 $364.62M -7.1% +1.4%
March 31, 2024 $359.48M -7.9% -4.9%
December 31, 2023 $377.95M -6.8% -3.6%
  • Aurinia Pharmaceuticals Inc. showed an increase of +54.0% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2017–2025 period, Aurinia Pharmaceuticals Inc.’s stockholders equity has grown by 226.7% (from $177.92 million to $581.33 million).
  • The most recent figure is from Aurinia Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment